Calliditas Therapeutics Presents Additional Data Analyses From Phase 3 NeflgArd Trial Of Nefecon In Primary IgA Nephropathy At ISN World Congress Of Nephrology 2024
Calliditas Therapeutics Presents Additional Data Analyses From Phase 3 NeflgArd Trial Of Nefecon In Primary IgA Nephropathy At ISN World Congress Of Nephrology 2024
Calliditas Therapeutics在2024年ISN世界肾脏病大会上公布了Nefecon治疗原发性IgA肾病的3期NefelGard试验的更多数据分析
Richard Philipson, Chief Medical Officer of Calliditas, said, "These additional data further reinforce the impact of Nefecon across the entire study population, irrespective of baseline UPCR levels or patient's racial and ethnic backgrounds."
Calliditas首席医学官理查德·菲利普森说：“这些额外的数据进一步强化了Nefecon对整个研究人群的影响，无论基线UPCR水平或患者的种族和族裔背景如何。”
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。